Chapter 2

L.L. Krens, J.M. Baas, H. Gelderblom and H.J. Guchelaar

Drug Discov Today. 2010 Jul;15(13-14):502-16

Therapeutic modulation of KRAS signaling in colorectal cancer

Abstract

KRAS has an important role in colorectal carcinogenesis and mutant *KRAS* leads to a permanently activated KRAS protein. To exert its biological activity, KRAS requires post-translational modification by prenylation.

KRAS modulation has become a promising concept for new therapies, mostly by interference with the mevalonate pathway and subsequently by the prenylation of KRAS. Clinical data of agents interfering with the mevalonate pathway and the prenylation of RAS are summarized and suggest that these agents might be effective when administered in combination with anticancer drugs that target KRAS. Here, we discuss the novel concept that modulation of KRAS might potentiate EGFR therapy by altering the KRAS phenotype.

Introduction

Colorectal cancer (CRC) is the second most common tumor type in the USA and accounts for 49,920 cancer deaths each year. It is, therefore, the second most common cause of cancer-related mortality in the USA, causing nearly 9% of all cancer-related deaths [1].

If diagnosed early, colorectal tumors can be cured by radical resection. Unfortunately, many patients are diagnosed with (distant) metastasis either during follow-up or at first presentation. A small subset of patients with metastasis confined to a single organ (mostly the liver) can be cured by resection. For the majority of patients with metastasized disease, however, the only treatment option is palliative systemic treatment. In the past decade, new chemotherapeutic agents for CRC have become available, such as irinotecan and oxaliplatin. For advanced or metastasized CRC patients failing 5-FU (or capecitabine or UFT (ftorafur plus uracil)), oxaliplatin and irinotecan, therapy with a monoclonal antibody against the epidermal growth factor receptor (EGFR) is advised, but only in patients with tumors not harboring an activating mutation in the *KRAS* gene. *RAS* has a key role in carcinogenesis, signal transduction and proliferation in colorectal carcinoma. Mutations in *RAS* are found in 30% of all cancers and are a potential target for therapy. This review focuses on the role of KRAS and the novel concept of modulating KRAS with statins, farnesyltransferase inhibitors, geranylgeranyltransferase inhibitors and bisphosponates in human colorectal carcinomas.

Search strategy

A systematic literature search in PubMed was conducted on 3 April 2009 using the following keywords and combinations: *KRAS*, (colorectal) carcinoma, farnesyltransferase inhibitors, geranylgeranyltransferase inhibitor, bisphosphonates, statins, EGFR inhibitors, cetuximab and panitumumab. Results were assessed by reviewing titles and abstracts, and relevant articles were retrieved. Cited references in these articles were used to find further relevant articles.

RAS proto-oncogenes

The *RAS* gene family consists of proto-oncogenes, which control cell growth in mammalian cells. Three different kinds of *RAS* oncogenes are known: *Kirsten RAS (KRAS), Harvey RAS (HRAS)* and *Neuroblastoma RAS (NRAS)*; these members of the *RAS* gene family are closely related and function in a similar way [2]. The *KRAS* gene encodes for a 21 kDa membrane-bound guanosine triphosphate (GTP)/guanosine diphosphate (GDP)-binding G protein. The KRAS protein serves as a switch between the EGFR and the nucleus, controlling downstream processes. To be active, hydrophilic KRAS requires post-translational modification by prenylation. Ras terminates in a CAAX sequence: a cysteine (C), two aliphatic amino acids (A) and any amino acid (X). The CAAX sequence is subject to post-translational farnesylation or geranylgeranylation. A 15-carbon chain from farnesylpyrophosphate (FPP) is added to the cysteine residue close to the carboxyl terminus, and this process is catalyzed by the enzyme farnesyl protein transferase (FTase). When FTase is inhibited, KRAS will be geranylgeranylated, thereby a 20-carbon chain of geranylgeranylpyrophosphate (GGPP) is added to ras catalyzed by geranylgeranyltransferase (GGTase) [3,4]. After isoprenylation of ras, the endopeptidase RCE1 protease removes the

AAX amino acids at the end of the carboxyl terminus. The new terminus is methylated by isoprenylcysteine carboxyl methyltranferase (ICMT) before RAS is transported to the cellular membrane. In NRAS and KRAS, the SH-group of cysteine residue is palmitoylated before transport to the membrane. As a consequence of post-translational modifications, KRAS becomes more hydrophobic and translocates from the cytosol to attach to the cell membrane by its farnesylgroup or geranylgeranylgroup [5–7] (figure 1). Membrane association of KRAS is crucial for its function in signaling and transforming activities.

Both FPP and GGPP are isoprenoids formed during the mevalonate pathway. FPP is a precursor for cholesterol, heme A, dolichols and ubiquinones, and GGPP can be formed out of FPP [8]. Inactivated KRAS is bound to GDP; activation occurs by the conversion of GDP to GTP by guanine exchange factors. In normal cells, the ratio of GDP and GTP is controlled by guanine exchange factors and GTPase-activating proteins (GAPs). Active KRAS is hydrolyzed by GAPs to return to an inactive state [9].



Figure 1: Post-translational modification of RAS. Abbreviations: F, farnesyl pyrophosphate; GG, geranylgeranylpyrophosphate; M, methylgroup; P, palmitoylgroup.

KRAS signaling

KRAS is situated in the inner cell membrane. Binding of a ligand to the EGFR activates a downstream process to the nucleus. This process activates major pathways in the cell: the RAS–RAF–mitogen-activated protein kinase (MAPK) and the PI3 kinase pathway (figure 2). KRAS has a key role in the RAS–RAF–MAPK pathway. Son of sevenless (SOS) is conformationally modificated by interaction with growth factor receptor bound protein 2. Activated SOS induces the KRAS pathway [10]. In RAS-RAF-MAPK signaling, KRAS activates serine–threonine kinase raf 1, which phosphorylates two MAPK kinases. These in turn phosphorylate other MAPKs. MAPKs translocate to the nucleus and activate transcription factors involved in proliferation [8,11]. Signaling via the PI3 kinase pathway activates AKT and thereby phosphoproteins, for example, p-GSK3 and p-AKT [12]. The tumor suppressor gene PTEN inhibits the PI3 kinase pathway.



Figure 2: Overview of EGFR-dependent intracellular signaling. Abbreviations: AKT, protein kinase B; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; ERK, extracellular signal-related kinase; GRB2, growth factor bound protein 2; KRAS-GDP, KRAS bound to guanine diphosphate; KRAS-GTP, KRAS bound to guanine triphosphate; MEK, mitogen-activated protein kinase; MTOR, mammalian target of rapamycin; PI3K, phosphatidyl-inositide-3-kinase; PTEN, phosphatase and tensin homolog; RAF, V-raf murine sarcoma viral oncogene homolog; SOS, son of sevenless.

KRAS mutations in cancer

KRAS mutations have an important role in tumorigenesis. In CRC, *KRAS* somatic mutations are thought to be involved in the transition of adenoma into carcinoma, contributing to tumor growth and atypia [13,14]. Mutant *RAS* is present in approximately 30% of all human cancers. *KRAS* mutational rate is high in some tumors; however, it is low in others (Table 1). Approximately 40% of CRCs have mutations in *KRAS*.

Table 1: Mutations of *NRAS, KRAS* and HRAS in different tumor types [32,93].

Tumor type	*RAS*	Frequency (%)
Colorectal carcinoma	*KRAS*	50
Lung adenocarcinoma (NSCLC)	*KRAS*	30
Pancreatic carcinoma	*KRAS*	90
Melanoma	*NRAS*	20
Thyroid carcinoma	*KRAS*, *NRAS*, *HRAS*	50
Myeloid disorders	*NRAS* (less frequently *KRAS*, *HRAS*)	30

Abbreviations: KRAS, Kirsten RAS gene; NSCLC, non-small cell lung carcinoma; NRAS, neuroblastoma RAS gene; HRAS, Harvey RAS.

Mutations are found in primary tumors and matched metastases. Most mutations are found in the primary tumor, indicating a role in early tumorigenesis. Mutations are occasionally found only in metastases; however, thus indicating such mutations can also occur during a later stage of disease [15].

The most frequent mutations in *KRAS* are guanine to adenine transitions and guanine to thymine transversions [16] with 90% of the somatic point mutations occurring in hotspot codon 12 (70%) or 13 (30%) in exon 1. Other, less frequent, mutations are known in codon 61, 62 and 146. The most frequent mutations in codon 12 and 13 are listed in Table 2. 6.6% of the somatic mutations are found outside codon 12 or 13 in codons 8, 9, 10, 15, 16, 19, 20 or 25[16]. A recent study showed mutations in codon 59, 61, 117 and 163 [17]. During tumor progression, more *KRAS* codon 12 mutations and fewer codon 13 mutations are found. In normal tissue, however, there is a balanced codons 12 and 13 mutation ratio [18].

Table 2: Common transitions and transversions in KRAS codon 12 and 13

Codon 12 mutations		
GGT (glycine) → AGT (serine)	G–A transition	G12S
GGT (glycine) → GAT (aspartate)	G–A transition	G12D
GGT (glycine) → TGT (cysteine)	G–T transversion	G12C
GGT (glycine) → GTT (valine)	G–T transversion	G12V
GGT (glycine) → CGT (arginine)	G–C transversion	G12R
GGT (glycine) → GCT (alanine)	G–C transversion	G12A
Codon 13 mutations		
GGC (glycine) → GAC (aspartate)	G–A transition	G13D
GGC (glycine) → TGC (cysteine)	G–T transversion	G13C
GGC (glycine) → GTC (valine)	G–T transversion	G13V
GGC (glycine) → CGC (arginine)	G–C transversion	G13R
GGC (glycine) → GCC (alanine)	G–C transversion	G13A
GGC (glycine) → AGC (serine)	G–A transition	G13S

Abbreviations: A, adenine; C, cytosine; G, guanine; T, thymine.

Different mutations in codon 12 or 13 have various effects on disease progression [19]. Guanine to adenine point mutations are associated with methylguanine methyltransferase epigenetic silencing [20]. Mutations leading to a 12-glycine residue (without a side chain) toward a residue with a side chain interfere with the geometry of KRAS and the ability of GTP to be hydrolyzed to return to an inactive state. These mutations cause impaired GTPase activity: KRAS binds GAP, but there is no activation of the GAP because of steric hindrance [21], and they permit a permanently active state causing growth and proliferation [22,23]. Consequently, mutant KRAS operates independently of activation of the EGFR and causes downstream processes [24].

No clear conclusions can be drawn from the studies regarding the influence of *KRAS* on the progression of colon cancer and, thus, the prognostic impact of *KRAS* mutation in colorectal carcinoma is unclear. Several studies link *KRAS* to worse prognosis, whereas others do not implicate a prognostic role for *KRAS* [25–31]. The RASCAL study was initiated to determine whether the presence of KRAS mutations in CRC patients is associated with poor prognosis. Initial results of this study suggested that *KRAS* mutational status is indeed associated with poorer disease-free survival and overall survival. The RASCAL II study, however, reported that only one specific mutation reduces disease-free and overall survival statistically significant and that KRAS mutational status in general is not a prognostic marker. Nevertheless, mutational status of *KRAS* is of great clinical relevance in CRC patients in predicting response to EGFR-inhibitor-based therapy. The RASCAL II study showed that only glycine to valine transversion on codon 12 had a statistically significant influence on interval between operation and relapse or death from any cause and on overall survival [19,32]. Post hoc analyses of two trials evaluating the EGFR inhibitors panitumumab and cetuximab in CRC showed lack of response to these agents in *KRAS* mutant patients [33,34]. Nowadays, EGFR inhibitor therapy in CRC is indicated only in patients free of mutations in codons 12 and 13 of the *KRAS* gene.

Testing for *KRAS* gene mutations

Currently, testing for *KRAS* mutations is not standardized. For the identification of *KRAS* mutations, different methods are being used; however, data about the accuracy of different tests are limited [12]. *KRAS* testing currently focuses on codon 12 or 13 mutations. Seven mutations in these codons contribute to more than 95% of all *KRAS* mutations. In real-time polymerase chain reactions, probes for the most common mutations in codons 12, 13 and sometimes 61 are applied. In direct sequencing analysis, all possible mutations of *KRAS* can be identified [35]. Many methods of *KRAS* testing are laboratory-based methods. The following methods are used for *KRAS* testing: gel electrophoresis assays, sequencing, allele-specific PCR assays and allele-discrimination-based allele-specific ligation detection reaction.

Allele discrimination is based on discrimination amplification efficiencies at low melting temperatures. Some assays are commercially available [36,37]. Juan et al. [38] compared testing methods (Histogenex, Genzyme, Invitek and Gentrix) from four independent commercial laboratories with their internal direct sequencing, and all but one (Invitek) were comparable with the internal direct sequencing method.

Tol et al. [36] compared two commonly used *KRAS* mutation tests, real time PCR and sequencing in DNA extracted from CRC samples. Both sequencing and real-time PCR are reliable *KRAS* testing assays with a sensitivity of 95.5% (95% confidence interval 91.7–97.9%) and 96.5% (95% confidence interval 93.0–98.6%), respectively.

A difficulty in *KRAS* testing occurs when a low volume of tumor material is available, for example because of pre-treatment with radiotherapy. In samples with less than 30% tumor cells, a *KRAS* mutation can be missed by sequencing. Obviously, high-quality *KRAS* testing is necessary because the *KRAS* status of a patient is used to determine clinical opportunities. The European Society of Pathology has started a Quality Assessment program for *KRAS* testing because of the lack of procedures and standardization (http://esp-pathology.org).

KRAS and pathogenetic pathways in CRC

In the progression toward CRC, pathological genetic changes occur. This review focuses on *KRAS*; however, other genetic changes have an important role and interplay in colorectal carcinogenesis. Early genetic abnormalities arise in adenomatous polyposis coli, *KRAS* and *BRAF* (v-raf murine sarcoma viral oncogene homolog B1). Mismatch repair gene mutation and *MLH1* mutation contribute to microsatellite instability. These pathological genetic changes lead to dysplastic crypt and (early) adenoma formation.

Further positive selection occurs for the mutation of TGFb receptor 2, insulin-like growth factor 2 receptor, *BAX*, loss of *SMAD4*, *TP53* and *PIK3CA*, which lead to further progression to carcinoma.

KRAS, BRAF, PTEN and *PIK3CA* are mediators of the down- stream signaling of the EGFR. Genetic alterations in these genes contribute to a different EGFR signaling. Oncogenic mutations in *RAS* and *BRAF* activate the MAPK signaling pathway. *BRAF* mutations occur in 13% of CRCs. *PIK3CA* encodes for PI3 kinase. PI3 kinase is controlled by PTEN, which could be lost in colorectal carcinoma. Figure 3 overviews the pathogenic changes and interplay in colorectal carcinoma [39,40].



Figure 3: Genetic alterations in colorectal carcinoma. Abbreviations: APC, adenomatous polyposis coli; BAX, BCL2-associated X protein; BRAF, V-raf murine sarcoma viral oncogene homolog; KRAS, Kirsten RAS gene; MMR, mismatch repair; MLH1, human mutL homolog 1; PIK3CA, phosphoinositide-3-kinase; catalytic, alpha polypeptide; PTEN, phosphatase and tensin homolog; SMAD4, SMAD family member 4; TGFBR2, transforming growth factor, beta receptor II; TP53, tumor protein p53.

Targeting KRAS as an anticancer therapy

Modulating KRAS signaling has become a promising concept for new cancer therapies. A variety of approaches, mostly interfering with the mevalonate pathway, 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA) reductase and prenylation of KRAS have been studied [41]. The mevalonate metabolites, FPP and GGPP, play an important part in the post-translational modification of KRAS and have become a target for different anticancer approaches. The effects of statins, bisphosphonates, FTIs, GGTIs, RAS converting enzyme 1 (Rce1) inhibitors and (soprenylcysteine carboxyl methyltransferase) ICMT inhibitors on the mevalonate pathway and indirectly on prenylation of KRAS (Fig. 4) and the results of phase I, II and III clinical studies are discussed.



Figure 4: Overview of the mevalonate pathway and inhibitors. The mevalonate pathway causes prenylation of ras, N-glycosylation of EGFR and membrane and steroid synthesis. Statins, bisphosphonates, farnesyltransferase inhibitors and geranylgeranyltransferase inhibitors have inhibitory effects on the mevalonate pathway and thus on prenylation of KRAS. Abbreviations: Acetyl-CoA (acetyl coenzyme A); EGFR, epidermal growth factor receptor; FTase, farnesyltransferase; FTIs, farnesyltransferase inhibitors; GGTase, geranylgeranyltransferase; GGTIs, geranylgeranyltransferase inhibitors; HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) (reductase),; -PP, -pyrophosphate.

Statins

Statins are HMG-CoA inhibitors, which suppress the cholesterol biosynthesis in humans by their inhibitory effect on the mevalonate pathway, thereby inhibiting the formation of low-density lipoprotein (LDL). Owing to upregulation of LDL receptors, the blood clearance of LDL also enhances, increasing the lipid-lowering effect of statins.

Besides the cholesterol-lowering effects, statins are believed to inhibit tumor cell growth and angiogenesis, induce apoptosis and impair tumor metastasis. Through inhibition of HMG-CoA, statins inhibit the formation of mevalonate, thereby affecting the synthesis of the isoprenoids FPP and GGPP. These substrates are used for farnesylation and geranylgeranylations of RAS and RHO. In addition, statins affect both angiogenesis and inflammation processes [5,42] and exert a role in chemoprevention by the inhibition of HMG-CoA reductase, which is upregulated in colon cancer cells [43]. *In vitro* studies have shown that statins suppress growth and induce apoptosis [44,45]. The clinical characteristics of colon cancer among statin users differ from non-users. The former have a lower tumor state, have a lower frequency of metastases, more frequently have a right-sited location of the tumor and have a significantly improved five-year survival rate (37% versus 33%, P-value < 0.01) [46].

The anticancer effects of statins have been studied in phases I, II, and III clinical trials in various malignancies (Table 3), with statin doses from 20 mg/day up to 45 mg/kg/day. Results vary, showing no (additional) effect of statins in multiple myeloma [47–49] and promising results in hepatocellular carcinoma [50]. Graf et al. [50] studied the addition of statins to transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma and found a significant gain in overall survival compared to TACE alone (median overall survival 20.9 months versus 12.0 months, P = 0.003).

Lee et al. [51] recently reported results of a trial adding simvastatin to irinotecan, leucovorin and 5-FU (FOLFIRI) as first-line therapy in CRC patients. They based the hypothesis on a synergistic effect of these therapies in preclinical research. Response rates and overall survival were similar to historical results of FOLFIRI alone, but time to progression was prolonged (9.9 months versus 6.7–8.5 months), and there was no additional toxicity.

These trials show promising activity of statins in solid tumors, yet further studies on statins in cancer therapy are needed.

Farnesyltransferase inhibitors

Prenylation is a necessary post-translational step for functional KRAS; for that reason, farnesyltransferase inhibitors (FTIs) and geranylgeranyltranferase inhibitors (GGTIs) have been developed as anticancer therapy. Besides KRAS, other GTPases that promote tumor progression are prenylated. FTase can recognize and prenylate tetrapeptides with a CAAX sequence. FTIs act through two mechanisms. FPP analogs selectively compete with FPP for binding to FTase and the CAAX sequence of KRAS. The peptidemimetics competes with RAS-CAAX for FTase; some FTIs compete via both mechanisms. By these mechanisms, FTIs inhibit farnesylation of not only ras proteins but also various other polypeptides, such as nuclear lamins A and B, skeletal muscle phophorylase kinase, transducin, cGMP phophodiesterase and the cell regulatory protein tyrosine phosphatases [52].

Table 3: Phase I, II, and III trials evaluating statins in cancer treatment

Study	Refs	Study design	Tumor type	Agent	Additional agent	n	Main results
Lee	[51]	Phase II	CRC	Simvastatin	FOLFIRI	49	TTP possibly prolonged; no effect on RR or OS
Graf	[50]	Phase III	HCC	Pravastatin	TACE	183	mOS 20.9 months versus 12.0 months
Lopes-Aguilar	[94]	Phase II	Brain stem tumors (pediatric)	Fluvastatin	Chemotherapy + thalidomide	9	RR 78%
Sondergaard	[47]	Phase II	Multiple myeloma	Simvastatin	None	6	RR 0%
van der Speck	[48]	Phase II	Multiple myeloma	Simvastatin	VAD	12	RR 8%
Schidmaier	[49]	Phase II	Multiple myeloma	Simvastatin	Bortezomib or bendamustine	6	RR 0%
Knox	[95]	Phase I	SCCHN/cervical carcinoma	Lovastatin	None	26	RR 0%; CBR 23%
Lersch	[96]		HCC	Pravastatin versus octreotide versus gemcitabine		58	mOS 7.2 versus 5 versus 3.5 months
Kim	[97]	Phase II	Gastric adenocarcinoma	Lovastatin	None	16	RR 0%
Kawata	[98]	Phase III	HCC	Pravastatin	TAE + oral 5FU	91	mOS 18 months versus 9 months
Larner	[99]	Phase I/II	Astrocytoma/ GBM	Lovastatin	±Radiation	18	RR 11%; CBR 17%
Thibault	[100]	Phase I	Solid tumors	Lovastatin	None	88	Lovastatin well tolerated up to 25 mg/ kg/day

Abbreviations: (m)OS, (median) overall survival; CBR, clinical benefit rate (i.e. complete and partial remission and stable disease); CRC, colorectal carcinoma; FOLFIRI, irinotecan, leucovorin and 5-FU; GBM, glioblastoma multiforme; HCC, hepatocellular carcinoma; RR, response rate (i.e. complete and partial remission); SCCHN, squamous cell carcinoma of head and neck; TA(C)E, transcatheter arterial (chemo)embolization; TTP, time to progression; VAD, vincristine, adriamycin, dexamethasone.

Four FTIs were tested in clinical trials worldwide: lonafarnib and tipifarnib (both oral compounds) have been tested in phase II and phase III studies (listed in Table 4), and BMS-214662 and L-778,123, administered intravenously, were tested in phase I studies. Some of the trials listed in Table 4 tested tipifarnib and lonafarnib in solid tumors, such as breast, pancreatic, colorectal, urothelial and brain tumors, but the results of these trials were disappointing. Sparano et al. recently published the results of a phase II trial testing the addition of tipifarnib to neo-adjuvant doxorubicin–cyclophosphamide in patients with clinical stage IIB–IIIC breast cancer. The trial included 44 patients, and a pathological complete remission was seen in 25%,

compared to 10–15% for chemotherapy alone according to historical results. Still, the role of tipifarnib in the treatment of solid tumors remains unclear and further study is needed. In hematologic malignancies, however, tipifarnib did show some single-agent activity, especially in elderly patients with poor risk and previously untreated acute myeloid leukemia. Lancet et al. [54] tested tipifarnib monotherapy in this population and observed a response rate of 23%. Tipifarnib was submitted to the FDA for the treatment of acute myeloid leukemia in elderly patients not applicable for standard chemotherapy in January 2005. In June 2005, however, the FDA filed a Not Approvable Letter, awaiting the results of subsequent phase III trials of tipifarnib for this indication [55–57]. Recently, the results of a phase III trial comparing tipifarnib with best supportive care in newly diagnosed acute myeloid leukemia in patients of 70 years or older were published. The results showed no effect of tipifarnib on survival (median survival, 107 days versus 109 days; P-value, 0.843) [58].

Activation of *KRAS* by mutation is associated with radiotherapy resistance. Preclinical studies *in vitro* and *in vivo* with FTIs showed that the radiosensitivity of cells might be improved. The potential synergistic effect for radiosensitization might be the inhibition of activated KRAS by the FTIs [59–61].

A phase I trial of L-778,123 (an FTI and GGTI) and radiotherapy in 12 patients with pancreatic cancer showed acceptable toxicity. In a patient-derived pancreatic cell line, radiosensitization was observed. In total, eight patients completed treatment, one patient showed partial response for six months, five patients showed stable disease (>2 months) and two patients were progressive [62].

Another phase I trial with L-788,123 with radiotherapy in nine patients with locally advanced head and neck or lung cancer showed a complete response in one patient and five patients with a partial response [63].

Table 4: Phase II and III trials evaluating FTIs in cancer treatment

Author	Refs	Study design	Tumor	Agent	Additional agent	n	Endpoints and results
Harrousseau	[58]	Phase III	AML	Tipifarnib	None	457	No effect on survival
Sparano	[53]	Phase II	Breast cancer	Tipifarnib	Doxorubicin and cyclophosphamide	44	RR 77%
Li	[101]	Phase II	Breast cancer	Tipifarnib	Fulvestrant	33	CBR 52%; target CBR (70%) not achieved
Lustig	[102]	Phase II	GBM	Tipifarnib	Radiotherapy	28	RR 0%; CBR 29%
Eckhardt	[103]	Phase II	Pancreatic cancer	Tipifarnib versus placebo	Gemcitabine	244	No effect of the addition of tipifarnib on survival
Ravoet	[104]	Phase II	MDS/AML	Lonafarnib	None	16	RR 6%
Feldman	[105]	Phase II	MDS/CML	Lonafarnib	None	67	RR 4%; HI 19%
Karp	[106]	Phase II	AML	Tipifarnib	None (maintenance)	48	mDFS 13.5 months
Fouladi	[107]	Phase II	Glioma	Tipifarnib	None	97	RR 2%
Johnston	[108]	Phase II	Breast cancer	Tipifarnib	None	120	RR 12%

Author	Refs	Study design	Tumor	Agent	Additional agent	n	Endpoints and results
Harousseau	[109]	Phase II	AML	Tipifarnib	None	252	RR 4%
Lancet	[54]	Phase II	AML	Tipifarnib	None	158	RR 23%
Cloughesy	[110]	Phase II	Glioma	Tipifarnib	None versus + EIAEDs	89	10% had PFS > 6 months; RR > 7%
Whitehead	[111]	Phase II	CRC	Tipifarnib	None	55	RR 7%
Borthakur	[112]	Phase II	CML	Lonafarnib	None	13	RR 18%
Macdonald	[113]	Phase II	Pancreatic cancer	Tipifarnib	None	53	mOS 2.6 months
Kim	[114]	Phase II	NSCLC	Lonafarnib	Paclitaxel	33	RR 10%; CBR 48%
Theodore	[115]	Phase II	Urothelial cancer	Lonafarnib	Gemcitabine	31	RR 32%
Winquist	[116]	Phase II	Urothelial cancer	Lonafarnib	None	19	RR 0%
Rosenberg	[117]	Phase II	Urothelial cancer	Tipifarnib	None	34	RR 6%; CBR 44%
Rao	[118]	Phase III	CRC	Tipifarnib versus placebo	None	268	CBR 24% versus 13%; no effects on PFS and OS
Heymach	[119]	Phase II	SCLC	Tipifarnib	None	22	RR 0%; mPFS 1.4 months
Van Cutsem	[120]	Phase III	Pancreatic cancer	Tipifarnib versus placebo	Gemcitabine	688	mOS 193 days versus 182 days
Kurzrock	[121]	Phase II	MDS	Tipifarnib	None	28	RR 11%; severe toxicity
Alsina	[122]	Phase II	Multiple myeloma	Tipifarnib	None	43	RR 0%; CBR 64%
Johnston	[108]	Phase II	Breast cancer	Tipifarnib	None	76	RR up to 14%
Adjei	[123]	Phase II	NSCLC	Tipifarnib	None	44	RR 0%; CBR 16%
Cohen	[124]	Phase II	Pancreatic cancer	Tipifarnib	None	20	RR 0%; mOS 19.7 weeks
Cortes	[125]	Phase II	Multiple myeloma/ CML	Tipifarnib	None	40	RR 18%
Sharma	[126]	Phase II	CRC	Lonafarnib	None	21	RR 0%; CBR 14%

Abbreviations: (m)DFS, (median) disease-free survival; (m)OS, (median) overall survival; (m)PFS, (median) progression-free survival; (N)SCLC, (non) small cell lung carcinoma; AML, acute myeloid leukemia; CBR, clinical beneficial rate (i.e. complete remission, partial remission and stable disease); CML, chronic myeloid leukemia; CRC, colorectal cancer; EIAEDs, enzyme-inducing antiepileptic drugs; GBM, glioblastoma multiforme; MDS, myelodysplastic syndrome; HI, hematologic improvement; RR, response rate (i.e. complete and partial remission).

GGTase inhibitors

Only inhibition of the farnesylation of KRAS by FTIs does not considerably affect its function, because KRAS can be geranylgeranylated as well. GGTase I geranylgeranylates KRAS when FTases are inhibited by FTIs. This fact triggered the development of GGTIs. GGPP analogs and CAAL peptidomimetics both act as GGTIs. Inhibition of KRAS prenylation might require co-treatment of FTIs with GGTIs and might explain the limited efficacy of the FTIs as single drug [56]. Moreover, in contrast to FTIs, GGTIs are able to block phosphorylation of both PDGF- and EGF-dependent tyrosine kinase receptors. GGTase inhibitors have been tested in preclinical studies and showed decreased tumor growth (cell-cycle arrest in G1 and apoptosis) in vivo and *in vitro* [65–67]. Possibly because of the preclinical toxicity of GGTase I inhibitors, up till now they have not proceeded to clinical stages.

Bisphosphonates

Bisphosphonates (BPs) inhibit isopentenyl diphosphatase isomerase and FPP synthase and probably also GGPP synthase, two metabolites in the mevalonate pathway. The newer nitrogen- containing BPs (e.g. pamidronate and zoledronic acid), inhibited farnesylation and geranylgeranylation of KRAS, resulting in a decrease of downstream signaling, inducing apoptosis [5,64]. Other observed effects of BPs on tumor cells are inhibition of migration through and adhesion and invasion to the extracellular matrix, so-called 'MMP activity'. At low concentrations, BPs inhibit the mevalonate pathway, whereas at higher concentrations, MMP activity is inhibited [68]. Furthermore, BPs reduce complications such as osteoporosis and skeletal morbidity caused by metastatic bone disease in metastatic and non-metastatic disease. In non-metastatic disease, BPs might prevent bone metastasis [69]; in metastatic disease, BPs might delay or prevent the complications caused by bone metastasis [70,71]. Clinical studies on BPs in cancer treatment have been performed, mainly focusing on endpoints regarding skeletal-related events such as fractures and bone pain. Some of these trials also focus on response-related endpoints, to investigate the role of BPs in survival in cancer.

Table 5 shows the phase II/III clinical trials on BPs in cancer treatment, not (only) focusing on skeletal-related events. The largest and most recent trial was published by Gnant et al. [72], who tested the effects of the addition of zoledronic acid to either goserelin and tamoxifen or goserelin and anastrozole in pre-menopausal women with endocrine-responsive early breast cancer. After a median follow-up of 47.8 months, a disease-free survival rate of 94.0% was seen in the group receiving endocrine therapy with zoledronic acid, compared to 90.8% in the group receiving only endocrine therapy (P = 0.01) [72].

Nowadays, BPs are known to reduce bone loss owing to hormone therapy (such as for breast and prostate cancer) and prevent skeletal-related events [70]. Despite the results published by Gnant et al. [72], however, there is no consensus about the effect of BPs on survival.

Table 5: Phase II and III clinical trials evaluating the effect of bisphosphonates on response related endpoints in malignancies.

Author	Refs	Study design	Tumor	Agent	Additional agent	n	Endpoints and results
Gnant	[72]	Phase III	Breast	Zoledronic acid	Tamoxifen and goserelin versus anastrozole and goserelin	1803	Significantly longer disease-free survival with zoledronic acid
James	[127]	Phase III	Prostate	Zoledronic acid	Androgen suppression ± docetaxel / ±celecobrix		Ongoing trial
Diel	[128]	Phase III	Breast	Clodronate	Adjuvant therapy	290	At 55 months follow up significantly improved PFS and OS with clodronate
Kristensen	[129]	Phase III	Breast	Pamidronate	Adjuvant chemotherapy and/or radiotherapy	953	No effect on occurrence of bone metastases
Kattan	[130]	Phase II	Prostate	Zoledronic acid	Docetaxel estramustine	27	PSA response in 52% RR 21%
Mason	[131]	Phase III	Prostate	Clodronate versus placebo	None	508	No effects on OS and bone metastases-free survival
Pavlu	[132]	Phase I/II	CML	Zoledronic acid	Imatinib	10	RR 0%
Di Lorenzo	[133]	Phase II	Prostate	Zoledronic acid	Docetaxel vinorelbine	40	PSA response in 32% RR in 40%
Di Lorenzo	[134]	Phase II	Prostate	Zoledronic acid	Gemcitabine prednisone	22	PSA response in 23% RR in 14%
Mitsiades	[135]	Phase III	Prostate	Zoledronic acid	None versus somatostatin analog and dexamethasone	38	RR 0% versus 65%. PFS and OS significantly improved
Lewis	[136]	Phase II	Melanoma	Apomine	None	42	RR 0%, mPFS 6.1 months
Bertelli	[137]	Phase II	Prostate	Zoledronic acid	Docetaxel	25	PSA response in 48%, mild toxicity
Figg	[138]	Phase II	Prostate	Alendronate	Ketoconazole and hydrocortisone	72	No significant differences in PFS, OS and RR
Tiffany	[139]	Phase II	Prostate	Zoledronic acid	Imatinib	15	No effects on pain and PSA
Dearnaley	[140]	Phase III	Prostate	Clodronate	None	311	Non-significant better BPFS and OS
Mardiak	[141]	Phase III	Breast	Clodronate versus placebo	Standard chemotherapy	73	Time to development of (bone) metastases 13 months versus 28 months

Abbreviations: (m)PFS, (median) progression-free survival; BPFS, bone progression-free survival; CML, chronic myeloid leukemia; OS, overall survival; PSA, prostate-specific antigen; PSA response, >50% PSA decline; RR, response rate (i.e. complete and partial remission).

Other post-prenylation inhibitors

After prenylation, KRAS undergoes endoproteolytic processing by the RCE1 protease and carboxyl methylation by ICMT. These enzymes, which act on both farnesylated and geranylgeranylated enzymes, could be targets for anticancer therapy.

Few small-molecule inhibitors of RCE1 and ICMT have been described so far. RPI, a prenylated CAAX peptide, competitively inhibits RCE1 as substrate analogs. Two types of ICMT inhibitors have been developed; both types act as mimics of substrates. The S-adenosylhomocysteines bind to methyltransferases and competitively inhibit the enzyme. In preclinical studies with cell lines, a partial block of proliferation was shown. Membrane-associated KRAS was reduced by 66% in one study, resulting in a decrease of downstream MEK/ERK signaling [73,74]. The second group of ICMT inhibitors contains derivatives of prenylcysteine: for example, N-acetyl-S-farnesyl-L-cysteine and N-acetyl-S-geranylgeranyl- L-cysteine. These substrates act also as substrates for ICMT; however, they target other processes in the cell as well [75].

EGFR antibodies and *KRAS*

The EGFR is a target for anticancer therapy. EGFR is expressed in normal tissues and different tumors. The EGFR is a 170-kDa transmembrane receptor with an extracellular ligand binding domain, a transmembrane domain and an intracellular tyrosine kinase membrane. There are four EGFR-related receptors; EGFR (HER1), HER2, HER3 and HER4. The binding of the ligand to the ligand-binding domain results in a conformational change, enabling the receptor to form an EGFR–EGFR homodimer or an EGFR–HER2, EGFR–HER3 or EGFR–HER4 heterodimer (figure 5). The active dimer cause ATP-dependent phosphorylation of EGFR through tyrosine kinases, which cause proliferation, inhibition of apoptosis, invasion and metastasis [76].



Figure 5: Dimerization of the EGFR. The binding of a specific ligand (e.g. EGF) causes a conformational change and results in homodimer or heterodimer formation. Abbreviations: EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; HER, human epidermal growth factor receptor.

Monoclonal EGFR antibodies bind the extracellular domain of EGFR, thereby blocking the ligand-binding region, and as a result, the EGFR tyrosine kinase activation is halted and ras signaling is inhibited [76,77]. Cetuximab can induce antibody-dependent cell-mediated cytotoxicity (ADCC) and downregulation and degradation of EGFR and in this way exerts its anti-tumor activity. For panitumumab, no ADCC has been described [78].

Two EGFR antibodies, cetuximab and panitumumab, have been registered. Cetuximab is registered for the treatment of metastasized colorectal carcinoma with EGFR overexpression in

KRAS wild type patients (monotherapy or in combination with chemotherapy), head and neck squamous cell carcinomas in combination with radiotherapy, and metastasized head and neck squamous cell carcinomas in combination with cisplatin-based chemotherapy. Panitumumab is registered for colorectal carcinoma with EGFR overexpression in *KRAS* wild type patients. Retrospective analysis of clinical trials showed a lack of clinical activity of cetuximab and panitumumab in patients with mutant *KRAS* because mutant *KRAS* operates independently of activation of the EGFR [24,33,34,79–88]. Table 6 represents clinical studies on the efficacy of cetuximab or panitumumab in patients with CRC with either mutant or wild type *KRAS* tumors. These results indicate that the efficacy of panitumumab and cetuximab (mono-) therapy is limited to patients with wild type *KRAS* tumors [33,34,89,90].

Table 6: Studies investigating KRAS and cetuximab and panitumumab and *KRAS* status in colorectal carcinoma.

Study	Refs	Treatment	*KRAS* status	RR	Median PFS	Median OS
Douillard	[91]	FOLFOX4 ± panitumumab	*KRAS* mutant	N/A	7.3 months	N/A
			KRAS wild type	-55	9.6 months	N/A
Peeters	[142]	FOLFIRI ± panitumumab	*KRAS* mutant	N/A	N/A	N/A
			KRAS wild type	-35	5.9 months	14.5 months
Van Cutsem	143 and 144	FOLFIRI ± cetuximab	*KRAS* mutant	102 (59.3)	7.6 months	17.5 months
			KRAS wild type	38 (36.2)	9.9 months	24.9 months
Bokemeyer	[81]	FOLFOX-4 ± cetuximab	*KRAS* mutant	17 (33)	5.5 months	N/A
			KRAS wild type	37 (60)	7.7 months	N/A
Tol	[88]	Capecitabine + oxaliplatin + bevacizumab ± cetuximab	*KRAS* mutant	(45.9)	8.1 months	17.2 months
			KRAS wild type	(61.4)	10.5 months	21.8 months
Amado	[33]	Panitumumab versus BSC	*KRAS* mutant	0 (0)	7.4 months	4.5 months
			KRAS wild type	21 (17)	12.3 weeks	6.8 months
Karapetis	[34]	Cetuximab versus BSC	*KRAS* mutant	(1.2)	1.9 months	4.8 months
			KRAS wild type	(1.28)	3.7 months	9.5 months
Lievre 2008		Cetuximab ± chemotherapy	*KRAS* mutant	0 (0)	9 weeks	10.1 months
			KRAS wild type	34 (43.6)	31.4 weeks	14.3 months
Lievre 2006	[85]	Cetuximab ± chemotherapy	*KRAS* mutant	0	N/E	6.9 months
			KRAS wild type	-65	N/E	16.3 months

Study	Refs	Treatment	*KRAS* status	RR	Median PFS	Median OS
De Roock	[82]	Cetuximab ± irinotecan	*KRAS* mutant	0 (0)	12 weeks	27.3 weeks
			KRAS wild type	27 (21)	24 weeks	43 weeks
Khambata-Ford	[24]	Cetuximab	*KRAS* mutant	3 (10)	59 days	N/E
			KRAS wild type	24 (48)	61 days	N/E
Di Fiore	[145]	Cetuximab plus chemotherapy	*KRAS* mutant	0 (0)	3 months	N/E
			KRAS wild type	12 (27.9)	5.5 months	N/E
Benvenuti	[79]	Cetuximab/panitumumab	*KRAS* mutant	1 (6.2)	N/A	N/E
			KRAS wild type	10 (31.2)	N/A	N/E
Frattini	[146]	Cetuximab	*KRAS* mutant	1 (10)	N/A	N/E
			KRAS wild type	9 (53)	N/A	N/E
Hecht	[147]	Bevacizumab + irinotecan based chemotherapy ± panitumumab	*KRAS* mutant	30	8.3 months	17.8 months
			KRAS wild type	54	10 months	N/A
		Bevacizumab + oxaliplatin based chemotherapy ± panitumumab	*KRAS* mutant	47	10.4 months	19.3 months
			KRAS wild type	50	9.8 months	20.7 months
Garm Spindler	[84]	Irinotecan + cetuximab	*KRAS* mutant	0 (0)	2.3 months	8.7 months
			KRAS wild type	-40	8.0 months	11.1 months
Bibeau	[80]	Panitumumab versus BSC	*KRAS* mutant	1 (4)	3.0 months	8.7 months
			KRAS wild type	10 (27)	5.5 months	10.8 months
Prenen	[87]	Irinotecan ± cetuximab	*KRAS* mutant	1 (1.3)	12 weeks	26 weeks
			KRAS wild type	37 (30.3)	24 weeks	45 weeks
Laurent-Puig	[148]	Cetuximab, remaining therapy unspecified	*KRAS* mutant	0 (0)	8.6 weeks	
			KRAS wild type	24 (68.4)	32 weeks	
Moroni	[149]	Chemotherapy ± cetuximab/ panitumumab	*KRAS* mutant	2 (20)	N/E	N/E
			KRAS wild type	8 (38)	N/E	N/E
Loupakis	[150]	Irinotecan + cetuximab	*KRAS* mutant	N/A	3.1 months	6.1 months

Study	Refs	Treatment	*KRAS* status	RR	Median PFS	Median OS
			KRAS wild type	N/A	4.2 months	13.5 months
Cappuzzo	[151]	Chemotherapy ± cetuximab	*KRAS* mutant	4 (9.5)	4.4 months	9.5 months
			KRAS wild type	10 (26.3)	5.4 months	10.8 months
Finocchiaro	[152]	Cetuximab	*KRAS* mutant	(6.3)	3.7 months	8.3 months
			KRAS wild type	(26.5)	6.3 months	10.8 months
Freeman	[153]	Panitumumab	*KRAS* mutant	0 (0)	N/A	N/A
			KRAS wild type	(10.5)	N/A	N/A
Di Nicolantonio	[83]	Chemotherapy ± cetuximab/ panitumumab	*KRAS* mutant	2 (6)	N/A	N/A
			KRAS wild type	22 (28)	N/A	N/A
Tabernero	[154]	Cetuximab	*KRAS* mutant	0 (0)		
			KRAS wild type	(27.6)		
		Chemotherapy + cetuximab	*KRAS* mutant	(31.6)	5.6 weeks	
			KRAS mutant	(55.2)	9.4 weeks	

Abbreviations: BSC, best supportive care; N/A, not available (yet); N/E, not evaluated; OS, overall survival; PFS, progression-free survival; RR, response rate. The values in parentheses are the percentages of patients with RR.

Alternative strategies

An alternative strategy to attack *KRAS* mutated cells would be to inhibit targets downstream of ras, such as mTOR (using RAD001), PI3 kinase (using BEZ235) or raf (using BAY 43-9006). One could consider combining inhibitors of targets within the RAS-RAF-MAPK and PI3 kinase pathway, thereby possibly creating inhibition comparable to targeting of the EGFR. Inhibitors of various targets within these pathways have been tested *in vivo* and are currently being studied in phase I/II clinical trials (http:// www.clinicaltrials.gov). Because the efficacy of these agents has not been proved yet, however, none of them are standard in cancer therapy. Such alternative strategies might be relevant in the future in the treatment of patients harboring *KRAS* mutations.

Future perspectives

KRAS mutation status has an impact on the therapeutic opportunities for patients with colorectal carcinoma. Both cetuximab and panitumumab are effective only in *KRAS* wild type patients,

and in *KRAS* mutant patients, a worse response has been reported [81,91]. Modulation of KRAS prenylation in *KRAS* mutant tumors might potentiate EGFR therapy [92] because the metabolites formed during the mevalonate pathway have a key role in prenylation and thereby post-translational activation of KRAS. Indeed, inhibition of the mevalonate pathway could influence the potential of KRAS to translocate from the cytosol toward the membrane and, thus, alter the KRAS phenotype toward the wild type. Combinations of EGFR antibodies to target the EGFR with KRAS modulators such as statins, BPs, FTIs or GGTIs inhibitors targeting RAS-RAF-MAPK signaling might augment the effect in patients with *KRAS* mutations. In (pre)clinical studies, further investigation should be done to elucidate the role of statins, FTIs, GGTIs, BPs, RCE1 inhibitors and ICMT inhibitors in CRC and the possibilities of therapeutic modulation of *KRAS* mutations.

References

1 Jemal, A. et al. (2009) Cancer statistics, 2009. CA Cancer J. Clin. 59, 225–249

2 Shimizu, K. et al. (1983) Three human transforming genes are related to the viral ras oncogenes. Proc. Natl. Acad. Sci. U. S. A. 80, 2112–2116

3 Rowell, C.A. et al. (1997) Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. J. Biol. Chem. 272, 14093–14097

4 Whyte, D.B. et al. (1997) K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem. 272, 14459–14464

5 Konstantinopoulos, P.A. et al. (2007) Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat. Rev. Drug Discov. 6, 541–555

6 Vogelstein, B. et al. (1988) Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 319, 525–532

7 Downward, J. (2003) Targeting RAS signaling pathways in cancer therapy. Nat. Rev. Cancer 3, 11–22

8 Graaf, M.R. et al. (2004) Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat. Rev. 30, 609–641

9 Buday, L. and Downward, J. (1993) Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor. Cell 73, 611–620

10 Roberts, P.J. and Der, C.J. (2007) Targeting the Raf–MEK–ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26 3291–3310

11 Fang, J.Y. and Richardson, B.C. (2005) The MAPK signaling pathways and colorectal cancer. Lancet Oncol. 6, 322–327

12 Heinemann, V. et al. (2009) Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treat. Rev. 35, 262–271

13 Bos, J.L. et al. (1987) Prevalence of ras gene mutations in human colorectal cancers. Nature 327, 293–297

14 Forrester, K. et al. (1987) Detection of high incidence of KRAS oncogenes during human colon tumorigenesis. Nature 327, 298–303

15 Artale, S. et al. (2008) Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J. Clin. Oncol. 26, 4217–4219

16 Brink, M. et al. (2003) KRAS oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis 24, 703–710

17 Wojcik, P. et al. (2008) KRAS mutation profile in colorectal carcinoma and novel mutation–internal tandem duplication in KRAS. Pol. J. Pathol. 59, 93–96

18 Kraus, M.C. et al. (2006) The balanced induction of KRAS codon 12 and 13 mutations in mucosa differs from their ratio in neoplastic tissues. Int. J. Oncol. 29, 957–964

19 Andreyev, H.J. et al. (1998) Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J. Natl. Cancer Inst. 90, 675–684

20 Sanchez-de-Abajo, A. et al. (2007) Molecular analysis of colorectal cancer tumors from patients with mismatch repair proficient hereditary nonpolyposis colorectal cancer suggests novel carcinogenic pathways. Clin. Cancer Res. 13, 5729–5735

21 Adjei, A.A. (2001) Blocking oncogenic Ras signaling for cancer therapy. J. Natl. Cancer Inst. 93, 1062–1074

22 Tong, L.A. et al. (1991) Crystal structures at 2.2 A resolution of the catalytic domains of normal ras protein and an oncogenic mutant complexed with GDP. J. Mol. Biol. 217, 503–516

23 Scheffzek, K. et al. (1997) The Ras–RasGAP complex: structural basis for GTPase activation

and its loss in oncogenic Ras mutants. Science 277, 333–338

24 Khambata-Ford, S. et al. (2007) Expression of epiregulin and amphiregulin and K- ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol. 25, 3230–3237

25 Anwar, S. et al. (2004) Systematic review of genetic influences on the prognosis of colorectal cancer. Br. J. Surg. 91, 1275–1291

26 Graziano, F. and Cascinu, S. (2003) Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough? Ann. Oncol. 14, 1026–1038

27 Klump, B. et al. (2004) Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature. Int. J. Colorectal Dis. 19, 23–42

28 Conlin, A. et al. (2005) The prognostic significance of KRAS, p53, and APC mutations in colorectal carcinoma. Gut 54, 1283–1286

29 Unknown author, (2005) ASCO conference highlights: potential markers of response in NSCLC. Signal 6, 12–16

30 Russo, A. et al. (2005) Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. Ann. Oncol. 16 (Suppl. 4), iv44–iv49

31 Castagnola, P. and Giaretti, W. (2005) Mutant KRAS, chromosomal instability and prognosis in colorectal cancer. Biochim. Biophys. Acta 1756, 115–125

32 Andreyev, H.J. et al. (2001) Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br. J. Cancer 85, 692–696

33 Amado, R.G. et al. (2008) Wild type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 1626–1634

34 Karapetis, C.S. et al. (2008) KRAS mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757–1765

35 Plesec, T.P. and Hunt, J.L. (2009) KRAS mutation testing in colorectal cancer. Adv. Anat. Pathol. 16, 196–203

36 Tol J. et al. (2009) High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. J. Cell Mol. Med. [Epub ahead of print]

37 van Krieken, J.H. et al. (2008) KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch. 453, 417–431

38 Juan, T. et al. (2008) A comparability study of 4 commercial KRAS tests. AACR Meeting Abstracts 2008 1811

39 Markowitz, S.D. and Bertagnolli, M.M. (2009) Molecular origins of cancer: molecular basis of colorectal cancer. N. Engl. J. Med. 361, 2449–2460

40 Walther, A. et al. (2009) Genetic prognostic and predictive markers in colorectal cancer. Nat. Rev. Cancer 9, 489–499

41 Friday, B.B. and Adjei, A.A. (2005) KRAS as a target for cancer therapy. Biochim. Biophys. Acta 1756, 127–144

42 Demierre, M.F. et al. (2005) Statins and cancer prevention. Nat. Rev. Cancer 5, 930–942

43 Hentosh, P. et al. (2001) Sterol-independent regulation of 3-hydroxy-3- methylglutaryl coenzyme A reductase in tumor cells. Mol. Carcinog. 32, 154–166

44 Sassano, A. and Platanias, L.C. (2008) Statins in tumor suppression. Cancer Lett. 260, 11–19

45 Jakobisiak, M. et al. (1991) Cell cycle-specific effects of lovastatin. Proc. Natl. Acad. Sci. U. S. A. 88, 3628–3632

46 Siddiqui, A.A. et al. (2009) For patients with colorectal cancer, the long-term use of statins is associated with better clinical outcomes. Dig. Dis. Sci. 54, 1307–1311

47 Sondergaard, T.E. et al. (2009) A phase II clinical trial does not show that high dose simvastatin has beneficial effect on markers of bone turnover in multiple myeloma. Hematol. Oncol. 27, 17–22

48 van der Spek, S.E. et al. (2007) High dose simvastatin does not reverse resistance to vincristine, adriamycin, and dexamethasone (VAD) in myeloma. Haematologica 92, e130–e131

49 Schmidmaier, R. et al. (2007) First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma. Eur. J. Haematol. 79, 240–243

50 Graf, H. et al. (2008) Chemoembolization combined with pravastatin improves survival in patients with hepatocellular carcinoma. Digestion 78, 34–38

51 Lee, J. et al. (2009) Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study. Cancer Chemother. Pharmacol. 64, 657–663

52 Crul, M. et al. (2001) Ras biochemistry and farnesyl transferase inhibitors: a literature survey. Anticancer Drugs 12, 163–184

53 Sparano, J.A. et al. (2009) Phase II trial of tipifarnib plus neoadjuvant doxorubicin–cyclophosphamide in patients with clinical stage IIB–IIIC breast cancer. Clin. Cancer Res. 15, 2942–2948

54 Lancet, J.E. et al. (2007) A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood 109, 1387–1394

55 Basso, A.D. et al. (2006) Lipid posttranslational modifications. Farnesyl transferase inhibitors. J. Lipid Res. 47, 15–31

56 Sebti, S.M. and Hamilton, A.D. (2000) Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene 19, 6584–6593

57 Cox, A.D. (2001) Farnesyltransferase inhibitors: potential role in the treatment of cancer. Drugs 61, 723–732

58 Harousseau, J.L. et al. (2009) A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. Blood 114, 1166– 1173

59 Brunner, T.B. et al. (2003) Farnesyltransferase inhibitors as radiation sensitizers. Int. J. Radiat. Biol. 79, 569–576

60 Cengel, K.A. et al. (2007) Oncogenic KRAS signals through epidermal growth factor receptor and wild type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells. Neoplasia 9, 341–348

61 Brunner, T.B. et al. (2004) Radiation sensitization by inhibition of activated Ras. Strahlenther. Onkol. 180, 731–740

62 Martin, N.E. et al. (2004) A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer. Clin. Cancer Res. 10, 5447–5454

63 Hahn, S.M. et al. (2002) A Phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer. Clin. Cancer Res. 8, 1065–1072

64 Walker, K. and Olson, M.F. (2005) Targeting Ras and Rho GTPases as opportunities for cancer therapeutics. Curr. Opin. Genet. Dev. 15, 62–68

65 Sun, J. et al. (1999) The geranylgeranyltransferase I inhibitor GGTI-298 induces hypophosphorylation of retinoblastoma and partner switching of cyclin- dependent kinase inhibitors. A potential mechanism for GGTI-298 antitumor activity. J. Biol. Chem. 274, 6930–6934

66 Sun, J. et al. (2003) Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice. Cancer Res. 63, 8922–8929

67 Vogt, A. et al. (1997) The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53- independent manner. J. Biol. Chem. 272, 27224–27229

68 Woodward, J.K. et al. (2005) Preclinical evidence for the effect of bisphosphonates and cytotoxic drugs on tumor cell invasion. Anticancer Drugs 16, 11–19

69 Diel, I.J. (2001) Bisphosphonates in the prevention of bone metastases: current evidence. Semin. Oncol. 28, 75–80

70 Aapro, M. et al. (2008) Guidance on the use of bisphosphonates in solid tumors: recommendations of an international expert panel. Ann. Oncol. 19, 420–432

71 Gralow, J. and Tripathy, D. (2007) Managing metastatic bone pain: the role of bisphosphonates. J. Pain Symptom Manage. 33, 462–472

72 Gnant, M. et al. (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 360, 679–691

73 Wang, H. et al. (1997) Inhibition of growth and p21ras methylation in vascular endothelial cells by homocysteine but not cysteine. J. Biol. Chem. 272, 25380–25385

74 Winter-Vann, A.M. et al. (2003) Targeting Ras signaling through inhibition of carboxyl methylation: an unexpected property of methotrexate. Proc. Natl. Acad. Sci. U. S. A. 100, 6529–6534

75 Winter-Vann, A.M. and Casey, P.J. (2005) Post-prenylation-processing enzymes as new targets in oncogenesis. Nat. Rev. Cancer 5, 405–412

76 Ciardiello, F. and Tortora, G. (2008) EGFR antagonists in cancer treatment. N. Engl. J. Med. 358, 1160–1174

77 Li, S. et al. (2005) Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7, 301–311

78 Imai, K. and Takaoka, A. (2006) Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer 6, 714–727

79 Benvenuti, S. et al. (2007) Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 67, 2643–2648

80 Bibeau, F. et al. (2009) Impact of FcgRIIa–FcgRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J. Clin. Oncol. 27, 1122–1129

81 Bokemeyer, C. et al. (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 27, 663–671

82 De Roock, W. et al. (2008) KRAS wild type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann. Oncol. 19, 508–515

83 Di Nicolantonio, F. et al. (2008) Wild type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 26, 5705–5712

84 Garm Spindler, K.L. et al. (2009) The importance of KRAS mutations and EGF61A > G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. Ann. Oncol. 20, 879–884

85 Lievre, A. et al. (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66, 3992–3995

86 Lievre, A. et al. (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 26, 374–379

87 Prenen, H. et al. (2009) PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin. Cancer Res. 15, 3184–3188

88 Tol, J. et al. (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic

colorectal cancer. N. Engl. J. Med. 360, 563–572

89 Allegra, C.J. et al. (2009) American Society of Clinical Oncology Provisional Clinical Opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 27, 2091–2096

90 Linardou, H. et al. (2008) Assessment of somatic KRAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta- analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 9, 962–972

91 Douillard, J. et al. (2009) Phase III study (PRIME/20050203) of panitumumab with FOLFOX4 compared to FOLFOX4 alone in patients with previously untreated metastatic colorectal cancer (mCRC): preliminary safety data. ASCO Meeting Abstracts

92 Mantha, A.J. et al. (2005) Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor. Clin. Cancer Res. 11, 2398–2407

93 Bos, J.L. (1989) ras oncogenes in human cancer: a review. Cancer Res. 49, 4682–4689

94 Lopez-Aguilar, E. et al. (2008) Phase II study of metronomic chemotherapy with thalidomide, carboplatin–vincristine–fluvastatin in the treatment of brain stem tumors in children. Arch. Med. Res. 39, 655–662

95 Knox, J.J. et al. (2005) A phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. Eur. J. Cancer 41, 523–530

96 Lersch, C. et al. (2004) Treatment of HCC with pravastatin, octreotide, or gemcitabine – a critical evaluation. Hepatogastroenterology 51, 1099–1103

97 Kim, W.S. et al. (2001) Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest. New Drugs 19, 81–83

98 Kawata, S. et al. (2001) Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br. J. Cancer 84, 886–891

99 Larner, J. et al. (1998) A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. Am. J. Clin. Oncol. 21, 579–583

100 Thibault, A. et al. (1996) Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin. Cancer Res. 2, 483–491

101 Li, T. et al. (2009) Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205. Ann. Oncol. 20, 642–647

102 Lustig, R. et al. (2008) Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease. Neuro-oncology 10, 1004–1009

103 Eckhardt, S.G. et al. (2009) Patient-reported outcomes as a component of the primary endpoint in a double-blind, placebo-controlled trial in advanced pancreatic cancer. J. Pain Symptom Manage. 37, 135–143

104 Ravoet, C. et al. (2008) Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study. Ann. Hematol. 87, 881–885

105 Feldman, E.J. et al. (2008) On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. Leukemia 22, 1707–1711

106 Karp, J.E. et al. (2008) Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features. Clin. Cancer Res. 14, 3077–3082

107 Fouladi, M. et al. (2007) A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma:

a Children's Oncology Group study. Cancer 110, 2535–2541

108 Johnston, S.R. et al. (2003) Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J. Clin. Oncol. 21, 2492–2499

109 Harousseau, J.L. et al. (2007) A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia. Blood 109, 5151–5156

110 Cloughesy, T.F. et al. (2006) Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J. Clin. Oncol. 24, 3651–3656

111 Whitehead, R.P. et al. (2006) Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: a Southwest Oncology Group study. Invest. New Drugs 24, 335–341

112 Borthakur, G. et al. (2006) Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. Cancer 106, 346–352

113 Macdonald, J.S. et al. (2005) A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study. Invest. New Drugs 23, 485–487

114 Kim, E.S. et al. (2005) Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/ resistant nonsmall cell lung carcinoma. Cancer 104, 561–569

115 Theodore, C. et al. (2005) Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers. Eur. J. Cancer 41, 1150–1157

116 Winquist, E. et al. (2005) A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer. Urol. Oncol. 23, 143–149

117 Rosenberg, J.E. et al. (2005) A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma. Cancer 103, 2035–2041

118 Rao, S. et al. (2004) Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J. Clin. Oncol. 22, 3950–3957

119 Heymach, J.V. et al. (2004) Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer. Ann. Oncol. 15, 1187–1193

120 Van Cutsem, E. et al. (2004) Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J. Clin. Oncol. 22, 1430–1438

121 Kurzrock, R. et al. (2004) Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J. Clin. Oncol. 22, 1287–1292

122 Alsina, M. et al. (2004) Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood 103, 3271–3277

123 Adjei, A.A. et al. (2003) Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 21, 1760–1766

124 Cohen, S.J. et al. (2003) Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J. Clin. Oncol. 21, 1301–1306

125 Cortes, J. et al. (2003) Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 101, 1692–1697

126 Sharma, S. et al. (2002) A phase II trial

of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. Ann. Oncol. 13, 1067– 1071

127 James, N.D. et al. (2009) Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial. BJU Int. 103, 464–469

128 Diel, I.J. et al. (2008) Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long- term follow-up. Ann. Oncol. 19, 2007–2011

129 Kristensen, B. et al. (2008) Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol. 47, 740–746

130 Kattan, J.G. et al. (2008) Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC). Invest. New Drugs 26, 75–79

131 Mason, M.D. et al. (2007) Oral sodium clodronate for nonmetastatic prostate cancer – results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). J. Natl. Cancer Inst. 99, 765–776

132 Pavlu, J. et al. (2007) Dual inhibition of ras and bcr-abl signaling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remission. Br. J. Haematol. 137, 423–428

133 Di Lorenzo, G. et al. (2007) Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. Eur. Urol. 52, 1020–1027

134 Di Lorenzo, G. et al. (2007) Phase II trial of gemcitabine, prednisone, and zoledronic acid in pretreated patients with hormone refractory prostate cancer. Urology 69, 347–351

135 Mitsiades, C.S. et al. (2006) Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer. Anticancer Res. 26, 3693–3700

136 Lewis, K.D. et al. (2006) A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma. Invest. New Drugs 24, 89–94

137 Bertelli, G. et al. (2006) Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients. Cancer Chemother. Pharmacol. 57, 46–51

138 Figg, W.D. et al. (2005) A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. J. Urol. 173, 790–796

139 Tiffany, N.M. et al. (2004) Imatinib mesylate and zoledronic acid in androgen- independent prostate cancer. Urology 63, 934–939

140 Dearnaley, D.P. et al. (2003) A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J. Natl. Cancer Inst. 95, 1300–1311

141 Mardiak, J. et al. (2000) Adjuvant clodronate therapy in patients with locally advanced breast cancer – long term results of a double blind randomized trial. Slovak Clodronate Collaborative Group. Neoplasma 47, 177–180

142 Peeters, M. et al. (2009) Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC). Eur. J. Cancer Suppl. 7, 9

143 Van Cutsem, E. et al. (2008) Kras status and efficacy in the Crystal Study: 1st-line treatment of patients with metastatic colorectal cancer (mCRC) receiving FOLFIRI with or without cetuximab. Ann. Oncol. 19 (Suppl. 8), viii4

144 Van Cutsem, E. et al. (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360, 1408–1417

145 Di Fiore, F. et al. (2007) Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br. J. Cancer 96, 1166–1169

146 Frattini, M. et al. (2007) PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br. J. Cancer 97, 1139–1145

147 Hecht, J.R. et al. (2009) A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol. 27, 672–680

148 Laurent-Puig, P. et al. (2007) Kras mutations in colorectal cancer is a predictive factor of response and survival in patient treated with cetuximab. Ann. Oncol. 18, vii81

149 Moroni, M. et al. (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 6, 279–286

150 Loupakis, F. et al. (2008) Analysis of Pten expression and Kras mutations on primaries (prim) and metastases (mets) to predict benefit from cetuximab plus irinotecan (Cetiri) in metastatic colorectal cancer (mCRC) patients (pts). Ann. Oncol. 19 (Suppl. 8), viii133–viii134

151 Cappuzzo, F. et al. (2008) Primary resistance to cetuximab therapy in EGFR FISH- positive colorectal cancer patients. Br. J. Cancer 99, 83–89

152 Finocchiaro, G. et al. (2007) EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer. J. Clin. Oncol. 25, 4021

153 Freeman, D.J. et al. (2008) Association of KRAS mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin. Colorectal Cancer 7, 184–190

154 Tabernero, J. et al. (2008) Correlation of efficacy to KRAS status (wt vs. mut) in patients (pts) with metastatic colorectal cancer (mCRC), treated with weekly (q1w) and q2w schedules of cetuximab combined with FOLFIRI. Presented at the 2008 Gastrointestinal Cancers symposium of the American Society of Clinical Oncology (ASCO), 25–27 January 2008, Orlando, USA